Dilaudid is an opioid medication owned by Fresenius Kabi Usa. It contains the active ingredient hydromorphone hydrochloride and is available in injectable dosage forms. Dilaudid was first authorised for market use on 11 January, 1984, and currently holds 2 drug patents, with none expired.
The generic version of Dilaudid is expected to be available after 12 March, 2034. This is because the last patent protecting this drug (US9248229) titled 'Packaging system for oxygen-sensitive drugs' is set to expire on that date. Therefore, no Dilaudid generic versions will be legally allowed until then.
Dilaudid is used to manage severe pain. Its active ingredient, hydromorphone hydrochloride, works by changing the way the brain and nervous system respond to pain, thus providing effective relief.
Dilaudid holds two patents. The most impactful one for the availability of Dilaudid generic is the patent (US9248229) titled 'Packaging system for oxygen-sensitive drugs', which will expire on 12 March, 2034. Below is the detail of the patent: